Imunon (IMNN) vs Pulmatrix (PULM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Imunon is the larger company by market cap ($6.0 million vs $5.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMNN | PULM |
|---|---|---|
| Share price | $1.07 | $1.53 |
| Market cap | $6.00M | $5.58M |
| 1-day change | -4.46% | +2.49% |
| EPS (TTM) | $-3.84 | $-1.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.39 | $5.24 |
| 52-week low | $1.03 | $1.16 |
| Distance from 52-week high | -80.15% | -70.83% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +1488.79% | — |
| Average volume | 155.30K | 24.09K |
| Shares outstanding | 5.61M | 3.65M |
| Employees | 20 | 2 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Imunon
IMNN stock →Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase for glioblastoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 20 employees
About Pulmatrix
PULM stock →Pulmatrix, Inc., a biopharmaceutical company, focused on development of novel inhaled therapeutic products to prevent and treat migraine and respiratory diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
IMNN vs PULM FAQ
Which is bigger, Imunon or Pulmatrix?
Imunon (IMNN) is larger, with a market capitalization of $6.00M compared with $5.58M for Pulmatrix (PULM).
Are Imunon and Pulmatrix in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.